secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001370053-22-000052
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront
-------------------------------------------------------------------------

- Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).
- Eligible for additional $10M milestone if Zejula approved for endometrial cancer by Dec 31, 2025.
- Current effective royalty rate is 0.5% of global Zejula net sales.
- Agreement includes customary covenants; Purchase Agreement to be filed in Q3 2022 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000052/0001370053-22-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005322000052/anab-20220909.htm
  HTML page:      https://secwatch.observer/filing/0001370053-22-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer